Paris, France and Boston, MA / AccessWire / May 23, 2023 / TISSIUM, a privately owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced that it has closed a Series D round of funding, consisting of €100 million from new and existing international investors. 50 million has been raised, including from the Fonds Strategique des Transitions managed by ISALT, Merieux Developpement. and returning Cathay Health, Credit Mutual Innovation and Sofinova Partners.
This latest funding round coincides with a period of important milestones for TISSIUM, particularly its first nerve repair product in Australia, human studies on COAPTIUM Connect, and several ongoing regulatory activities. The financing will allow TISSIUM to continue to execute on its growth plan, funding the company to commercialize its first products in nerve and hernia repair, and fuel the expansion of its pipeline of products and its platform.
As TISSIUM adds to its platform with products in new therapeutic areas, it will continue to leverage rapid international expansion, in-house production and state-of-the-art manufacturing facilities, as well as entering into partnerships in certain verticals.
Christophe Bancel, CEO of TISSIUM, said, “With the conclusion of our Series D financing round, TISSIUM is well positioned to finance the commercialization of its first products. This funding allows us to accelerate our progress toward our goal of scaling up the tissue significantly strengthens our ability to rebuild for patients. We look forward to continuing our work to drive innovation in the space and develop products that make a difference in patients’ lives.”
About Tisium:
TISSIUM, a privately owned medtech company based in Paris, France and Boston, USA, is dedicated to the development and commercialization of products derived from its unique biopolymer platform. The company’s products will address a number of unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of products that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the company has a pipeline of seven products across three verticals, which include sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue regeneration process in a unique way. In addition, the company develops complementary delivery and activation tools for enhanced performance and utility of its products.
TISSIUM’s technology is based on world-class research and intellectual property derived from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
For more information, please visit: www.TISSIUM.com
Follow us on LinkedIn, Twitter @TISSIUMtech.
,
Contact
Investor Relations
Romain Attard – Chief Financial Officer [email protected]
Tel: +33 1 76 21 72 28 Twitter: @TISSIUMtech
Press
Jeanine Timberlake [email protected]
Tel: +1 646-770-8858
Source: Tisium
View the source version on Accesswire.com:
Source: www.bing.com
